Sveriges mest populära poddar
Bloomberg Intelligence
NyheterNäringsliv

Merrimack's Mulroy on Success of Pancreatic Drug Onivyde(Audio)

11 min•10 maj 2016

(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Bob Mulroy, CEO of Merrimack Pharmaceuticals, on biotech earnings, consumer health and oncology, and its product pipeline. Broadcasting live from the Boston Convention and Exhibition Center.

See omnystudio.com/listener for privacy information.

Fler avsnitt av Bloomberg Intelligence

Visa alla avsnitt av Bloomberg Intelligence
CoreWeave Shares Soar After Booming AI Demand Boosts Outlook
•26 min
Apollo Inks $2.6 Billion Financing Deal With NY Yankees
•21 min
Intel to Sell $15 Billion in Stock After AI Boosts Demand
•22 min
Bloomberg Money: Credit Card Indicators and Golf's Changing Fanbase
•43 min
Under Armour Cuts Sales View on Softer Demand Around the World
•22 min
Warner Bros. Sales Fall on Loss of NBA, Weak Film Slate
•28 min
SpaceX’s $101 Billion Unlock Heaps Pressure on Battered Shares
•27 min
Earnings Special: SpaceX’s AI Splurge Puts a Damper on Debut Earnings After IPO
•20 min
Palantir Jumps After ‘Otherworldly Demand Lifts Outlook
•22 min
Visa to Buy Fraud-Prevention Firm BioCatch for $2.4 Billion
•22 min

Bloomberg Intelligence med Bloomberg finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.